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Introduction
A low vitamin D level is one of the factors most con-
sistently associated with multiple sclerosis (MS).1 
Yet, it is not well understood at which age an adequate 
exposure might be especially important and an inter-
vention optimally timed to modify MS risk.2
Observational studies investigating the timing of 
exposure reached different conclusions regarding 
the possibly most susceptible postnatal period: 
childhood,3 adolescence,4 childhood and adoles-
cence,5 adulthood.6 Migration and space-time cluster 
studies also pointed to different postnatal suscepti-
bility periods,7–10 though these findings could also 
reflect the effect of other environmental risk 
factors.2 Furthermore, lower vitamin D exposure and 
serum levels during the prenatal phase have been 
associated with increased risk of MS later in life and 
could mark an independent susceptibility period.11–13
Serum vitamin D levels are influenced by sun expo-
sure and diet.1 Cod liver oil is an important dietary 
vitamin D source in high-latitude countries like 
Norway where there is no sun-induced vitamin D pro-
duction during the winter.14 Norwegian Health 
Authorities have recommended 5 ml of cod liver oil 
daily (400 IU of vitamin D) for more than 60 years to 
prevent diseases like rickets, formerly more prevalent 
in areas with little access to vitamin D-rich fatty 
fish.15 A survey from 1997 estimated that about 35% 
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Background: Low vitamin D levels have been associated with an increased risk of multiple sclerosis 
(MS), although it remains unknown whether this relationship varies by age.
Objective: The objective of this paper is to investigate the association between vitamin D3 supplementa-
tion through cod liver oil at different postnatal ages and MS risk.
Methods: In the Norwegian component of the multinational case-control study Environmental Factors In 
Multiple Sclerosis (EnvIMS), a total of 953 MS patients with maximum disease duration of 10 years and 
1717 controls reported their cod liver oil use from childhood to adulthood.
Results: Self-reported supplement use at ages 13–18 was associated with a reduced risk of MS (OR 0.67, 
95% CI 0.52–0.86), whereas supplementation during childhood was not found to alter MS risk (OR 1.01, 
95% CI 0.81–1.26), each compared to non-use during the respective period. An inverse association was 
found between MS risk and the dose of cod liver oil during adolescence, suggesting a dose-response rela-
tionship (p trend = 0.001) with the strongest effect for an estimated vitamin D3 intake of 600–800 IU/d 
(OR 0.46, 95% CI 0.31–0.70).
Conclusions: These findings not only support the hypothesis relating to low vitamin D as a risk factor for 
MS, but further point to adolescence as an important susceptibility period for adult-onset MS.
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of the Norwegian population and 50% of those aged 
60–79 were still using the supplement on a daily 
basis.16
As the literature is inconsistent in delimiting a critical 
window in which vitamin D might act, we investigated 
the association between the postnatal timing of cod 
liver oil supplementation, an important oral vitamin D 
source in Norway, and the risk of developing MS.
Methods
The EnvIMS study
The multi-national multicenter case-control study of 
Environmental Factors In Multiple Sclerosis 
(EnvIMS) was launched to investigate environmental 
risk factors for MS and examine possible differences 
between distinct populations. A self-administered 
postal questionnaire (EnvIMS-Q) was designed 
including detailed questions about age-specific past 
exposures such as sun habits, diet, supplement use, 
past medical history, lifestyle, occupational and hor-
monal factors.17 The questionnaire has been assessed 
for acceptability, feasibility and reliability.17 The 
complete study design and methodology has been 
published elsewhere.17
The Norwegian component of the EnvIMS study was 
approved by the Regional Ethical Committee for 
Medical and Health Research for Western Norway (n. 
11, 18.12.2008). All eligible study participants 
received an invitation to participate in the form of an 
information letter explaining the study objectives, rel-
evance and instructions for participation. Completion 
and return of the questionnaire implied participants’ 
informed consent.
Study population
These analyses used the Norwegian EnvIMS data col-
lected in 2008. The cases, diagnosed according to the 
McDonald criteria,18 were recruited from the 
Norwegian MS-registry and Biobank.19 Only patients 
with disease duration shorter than 10 years were eligi-
ble for participation. Of the 1368 invited cases, 953 
(69.7%) returned the questionnaire. The response rate 
was 72% among women as compared to 64.6% in men.
Controls, frequency-matched on age and sex, were 
randomly selected in a 4:1-ratio from the population-
based National Registry in Norway (Folkeregisteret). 
Of the 4728 invited controls, 1717 (36.3%) partici-
pated. The response rate in women was again higher 
than in men (39.4% vs. 29.4%).
Exposure, outcome and covariates
Cod liver oil is an important source of vitamin D in 
the Norwegian population.16 The recommended one 
teaspoon (two capsules) daily of cod liver oil (5 ml) of 
the most commonly used Norwegian brand (Möller’s, 
Axellus AS, Oslo) contains 10 μg (400 IU) of vitamin 
D3, 250 μg of vitamin A, 10 mg of vitamin E and 1.2 
g of the omega-3 fatty acids EPA and DHA. A 
Norwegian survey estimated that the majority of con-
sumers use one tablespoon (15 ml) as a serving size.20
Given the importance of cod liver oil as a source of 
vitamin D in Norway, the use of this supplement was 
explored in several questions in the EnvIMS-Q. 
Participants were asked to report whether they had 
used cod liver oil or capsules “never” or at ages “0–
6,” “7–12,” “13–15,” “16–18,” “19–24” and “25–
30.” The age-scale was adapted to the Norwegian 
school system. Additionally, the frequency of supple-
ment use at ages 13–19 during the winter and the rest 
of the year was explored using two separate variables 
on a six-point scale including “never/seldom,” “1–3 
times/month,” “1 time/week,” “2–3 times/week,” 
“4–6 times/week” and “7+ times/week.” Another 
question classified the usual quantity of cod liver oil 
consumed at each serving during the same period 
into “no use,” “half a teaspoon,” “one teaspoon,” 
“half a tablespoon” and “one tablespoon or more.” 
The special interest of the investigators in this period 
was based on previous findings indicating that ado-
lescence might be especially important for MS risk 
modification.21
Further, data on important covariates were retrieved 
from the questionnaire. The level of sun exposure was 
estimated by summer outdoor activity at ages “0–6,” 
“7–12,” “13–15,” “16–18,” “19–24,” “25–30” and “in 
recent years,” and quantified as “not that often,” “rea-
sonably often,” “quite often” and “virtually all the 
time.” The frequency of consumption of vitamin 
D-rich fatty fish at main meals at ages 13–19 was 
explored on a six-point scale with “never,” “1 time/
month,” “2–3 times/month,” “1 time/week,” “2 times/
week” and “3 and more times/week” for a) “herring,” 
b) “mackerel,” c) “halibut, flounder” and d) “salmon, 
trout,” respectively. From the information elicited 
about infectious mononucleosis, past occurrence of 
the disease was used as covariate (“yes,” “no” or “I 
don’t remember”). Participants also reported their 
body shape at five-year age intervals based on a nine-
point scale derived from body sketches,22 a figure rat-
ing scale, which has been shown to reflect well 
individuals’ body mass index (BMI).23,24 Information 
on the smoking habits (smoking onset never or after 
versus before MS onset) and the participants’ level of 
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education (elementary, middle, high school or univer-
sity) was also included in the analyses.
Finally, participants reported whether they had a fam-
ily history of MS (affected parent, sibling or child) 
and whether they had asked their parents or another 
person for help in recalling information.
Statistical analyses
Statistical analyses were performed using STATA 
13.1 (StataCorp, College Station, TX, USA). The 
associations between exposure and outcome were 
estimated through logistic regression and reported as 
odds ratios (OR) with 95% confidence intervals (CIs). 
All estimates were adjusted for sex and year of birth 
(six-year categories to create balanced subgroups).
According to the distribution of age at disease onset 
in the cases, an index age with corresponding distri-
bution was assigned to controls taking into account 
age at time of study. Participants were considered 
exposed only if the exposure of interest occurred 
before the index postnatal age or age at disease onset. 
Participants exposed only after this period were con-
sidered unexposed.
Based on reported cod liver oil use at different ages, 
three variables were created: 1) cod liver oil use dur-
ing childhood (ages 0–12) regardless of use during 
the other periods compared to no use during child-
hood, 2) cod liver oil use during adolescence (ages 
13–18) regardless of use during the other periods 
compared to no use during adolescence and 3) cod 
liver oil use during adulthood (ages 19–30) regardless 
of use during the other periods compared to no use 
during adulthood. The effect of these variables was 
estimated in i) separate models adjusted for age and 
sex, ii) simultaneously in the same model and finally 
iii) also adjusted for different covariates.
Additionally, MS risk was compared for cod liver oil 
use continuously from birth up to different ages to 
investigate whether the duration of exposure was 
important. Information about frequency and quantity 
of supplement use at ages 13–19 was analyzed both as 
a categorical and a continuous variable using those 
who reported never having taken cod liver oil or cap-
sules during a certain season as reference.
Consumption frequency of fatty fish during adoles-
cence was examined by assigning scores between 0 
and 5 to each participant to account for how frequently 
on the six-point scale “herring,” “mackerel,” “halibut, 
flounder” and “salmon, trout,” respectively, were 
consumed. These scores were added up to an overall 
score ranging from 0 to 20 reflecting the fatty-fish 
consumption. To facilitate analyses of the overall 
score, a quintile-inspired five-point scale from 1 to 5 
was created grouping overall scores of 0, 1–2, 3–4, 
5–6, ⩾7 and analyzed as a continuous variable.
Further, reported sun exposure during the summer at 
ages 0–12, 13–18 and 19–30, history of infectious 
mononucleosis, smoking prior to MS onset, body size 
at age 15, frequency of consumption of oily fish at 
ages 13–19 and years of education were added to the 
model to adjust for possible confounding. In a second 
step interaction terms were created to test for effect 
modification by sex and age at disease onset.
Results
Mean study age and sex distribution were similar in 
both groups (Table 1). Cases were significantly more 
likely than controls to have smoked before MS onset, 
experienced infectious mononucleosis, reported a 
lower educational level, a large body size at age 15 and 
infrequent summer sun exposure during adolescence.
Timing of cod liver oil use
Supplementation habits did not vary with sex, but 
with age at the time of study. Supplementation during 
childhood, adolescence and adulthood was more 
common among participants born before 1962.
Cod liver oil use was reported by 54.4% of cases and 
55.9% of controls during at least one of the age 
ranges of interest between birth and age 30. 
Information on the age-specific supplementation 
was missing for 11.6% of participants. The associa-
tion between the risk of developing MS and cod liver 
oil use varied considerably depending on the timing 
of the supplementation (Table 2). A marked inverse 
association was observed for intake at ages 13–18 
after adjusting for age, sex and supplementation dur-
ing the other periods. Neither cod liver oil use during 
childhood nor adult life was associated with reduced 
disease risk compared to non-use during those 
periods.
The association between cod liver oil supplementa-
tion during adolescence and MS risk was not mean-
ingfully altered after adjusting for sun exposure, 
infectious mononucleosis, smoking, body size, oily 
fish consumption and education. No significant dif-
ferences were seen in the effect between men and 
women and according to age at disease onset (data not 
shown).
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We observed that 404 cases (42.4%) and 368 controls 
(21.4%) asked for help in completing the question-
naire. Of these, 34.1% vs. 42.2% used cod liver oil dur-
ing childhood, 19.8% vs. 30.2% during adolescence 
and 15.2% vs. 19.4% during adulthood, comparing 
cases and controls, respectively. When restricting the 
analysis of the fully adjusted model 3 (Table 2) to those 
asking for help, the pattern of association remained 
similar. The respective OR (95% CI) were 0.99 (0.66–
1.49) for childhood, 0.67 (0.42–1.06) for adolescence 
and 0.99 (0.64–1.54) for adulthood use.
Continuous supplementation from birth up to a cer-
tain age was increasingly more strongly associated 
with a reduced MS risk the longer the supplementa-
tion lasted, except for the longest period from birth to 
age 30 (Figure 1).
Supplementation during adolescence
Supplementation during adolescence was further ana-
lyzed for seasonality, frequency and habitual serving 
size.
The habit of using (liquid) cod liver oil during adoles-
cence was more common during the winter (33.7% 
and 43.6%) than the rest of the year (19.7% and 
23.9%), both in cases and controls. Information was 
missing for 15.9% of participants for intake during 
winter and 29.3% during the rest of the year. The fre-
quency of intake most often reported during adoles-
cence in the winter, if any, was “7+ times a week” 
both for cases (41.8%) and controls (39.3%). The 
serving size most commonly reported was “1 table-
spoon” for cases (58.7%) and controls (64.3%).
Table 3 shows the association between MS risk and 
increasing doses of vitamin D3 as estimated from the 
frequency and quantity of supplementation in the 
winter during adolescence, suggesting a dose-
response relationship (p trend = 0.001) and the strong-
est protective effect for 600–800 IU/d. The estimates 
did not substantially change after adjusting for a 
selection of confounders (Table 3), nor after also add-
ing family history of MS into the model.
The association was significant for supplementation 
only during the winter. For the supplement use in 
Table 1. Selected characteristics of the Norwegian participants in EnvIMSa,b.
Cases (n = 953) Controls (n = 1717)
Age at study, mean (SD) 44.8 (10.5) 46.0 (10.8)
Male, n (%) 286 (30.0) 461 (26.9)
Age at disease onset, mean (SD) 37.6 (10.2)g n.a.
Disease duration, mean (SD) 7.2 (2.7)g n.a.
Smoking before MS onsetc, n (%) 545 (58.9) 853 (50.7)
Infectious mononucleosis, n (%)  
 “Yes” 160 (17.3) 155 (9.3)
 “No” 729 (78.7) 1486 (88.8)
 “I don’t remember” 37 (4.0) 33 (2.0)
Educational level, n (%)  
 High school or lower 538 (57.1) 802 (47.3)
 University career 402 (42.7) 890 (52.5)
Body size at age 15, n (%)d  
 Normal (silhouette 1–4)e 794 (87.0) 1486 (89.5)
 Large (silhouette 5–9)f 119 (13.0) 174 (10.5)
Summer sun exposure, n (%)  
 Lower vs. higher at age 13–15 302 (32.7)/623 (67.4) 456 (27.4)/1210 (72.6)
 Lower vs. higher at age 16–18 487 (52.4)/443 (47.6) 779 (46.8)/885 (53.2)
EnvIMS: Environmental Factors In Multiple Sclerosis; SD: standard deviation; n: count; n.a.: not applicable.
aMissing data for covariates ranging from 0% to 3.6%.
bCases asked significantly more often for help than controls to recall information when filling out the questionnaire (mother: 34.5 vs. 
17.2%, father: 6.9 vs. 2.5%, other person: 8.3% vs. 4.2%).
cOnly 0.9 % in this group smoked less than three years.
dBased on Stunkard’s figure rating scale.
eBody mass index (BMI) ranges from 18.9 to 23.5 kg/m2.
fBMI ranges from 26.1 to 43.3 kg/m2 including overweight and obesity.
gBased on data from the Norwegian MS-registry and Biobank.
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other seasons we found no evidence of an association 
between doses of cod liver oil during adolescence and 
MS (OR 1.03, 95% CI 0.84–1.26, p trend = 0.773, 
adjusted for supplementation during adolescence in 
the winter and the covariates listed in the methods).
Fish consumption
Consumption of fatty fish during adolescence was 
associated with a significant reduction in risk for later 
MS development (OR 0.92, 95% CI 0.86–0.99, p 
trend = 0.047, adjusted for all covariates mentioned in 
Table 2. Association between cod liver oil use at different ages and the risk of MS.
Use compared to no use of cod liver oil during
 Childhood (0–12 y)a Adolescence (13–18 y)a Adulthood (19–30 y)a
Cases n (%) 301 (31.8) 196 (20.6) 165 (17.4)
Controls n (%) 631 (36.9) 473 (27.6) 309 (18.0)
 OR (95% CI)b OR (95% CI)b OR (95% CI)b
Model 1c 0.82 (0.69–0.97)f 0.70 (0.58–0.85)g 1.00 (0.81–1.24)
Model 2d 1.01 (0.81–1.26) 0.67 (0.52–0.86)h 1.17 (0.93–1.47)
Model 3e 1.01 (0.79–1.29) 0.72 (0.55–0.96)f 1.18 (0.92–1.51)
MS: multiple sclerosis; y: years; n: count; OR: odds ratio; CI: confidence interval.
aContinuous or periodical use regardless of prior and subsequent use.
bOR of MS for age at disease onset after the exposure period of interest by cod liver oil use during specific age periods compared to 
no use during the same period.
cModel 1: Separate model for each age period. Adjusted for age and sex.
dModel 2: All three age periods included in the same model. Adjusted for age and sex.
eModel 3: All three age periods included in the same model. Adjusted for age, sex, smoking before disease onset, history of infec-
tious mononucleosis, sun exposure, body shape at age 15, education, and consumption of fatty fish.
fP value < 0.05.
gP value < 0.0001.
hP value < 0.005.
Figure 1. Association between cod liver oil use during increasingly longer age-periods and MS risk.
MS: multiple sclerosis; OR: odds ratio; CI: confidence interval. n: count.
OR of MS in groups with cod liver oil use continuously from birth up to a specific age compared to those who reported no use in the past 
and number of cases and controls.
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the methods). This OR was related to one step on the 
five-point scale and is equivalent to an OR of 0.72 
comparing most frequent with no fish consumption. 
When further adjusting for cod liver oil use during 
adolescence, the result did not meaningfully change, 
but was no longer significant (OR 0.93, 95% CI 0.86–
1.01, p trend = 0.085).
Discussion
We found an inverse association between MS risk and 
cod liver oil supplementation during adolescence and 
a dose-response protective effect suggested for higher 
dosages of vitamin D consumed through cod liver oil. 
However, no association was observed for supplemen-
tation during childhood or adulthood. These findings 
suggest that adolescence might be an especially sus-
ceptible period for disease risk modification through 
dietary vitamin D and are in line with previous obser-
vational4,21 and experimental25 studies. Other environ-
mental risk factors like infectious mononucleosis,26 
high BMI24 and other lifestyle factors27 have also been 
suggested to act mainly during adolescence.
Previous studies in the same area found that sun expo-
sure through outdoor activity during adolescence was 
associated with a decreased disease risk only when 
exposure occurred during the summer,4,28 while the 
association between MS and cod liver oil use during 
adolescence in the present study was only significant 
for intake during the winter when sun-induced vita-
min D-production ceases. These seasonal differences 
suggest that the risk-modifying effect is vitamin D 
mediated.
A low vitamin D level is one of the risk factors most 
consistently associated with an increased risk of MS. 
A prospective study reported a decreased MS risk 
among adult nurses comparing supplemental intake of 
⩾400 IU/d of vitamin D to no intake.6 However, it is 
unclear how vitamin D levels in adulthood correlate 
with those during adolescence.
Our findings indicate an especially sensitive period 
during adolescence for MS risk modification but 
probably not the only one.21 Higher doses of vitamin 
D may be needed during childhood and adulthood to 
reach the same degree of risk modification as during 
adolescence.21,25 Even though we did not find an 
association between overall cod liver oil use during 
childhood or adulthood and MS risk, we could not 
evaluate whether a protective effect was restricted to 
high-dose users at these ages, as this information was 
not collected.
A prospective study in the United States (US) did 
not find an association between total recalled die-
tary vitamin D intake during adolescence and MS 
risk.29 Intake of ⩾400 IU/d of vitamin D from mul-
tivitamins during adolescence showed, however, a 
nonsignificant reduced MS risk of an order of mag-
nitude similar to the findings in our study under the 
rare-disease-assumption.29 Power might not have 
been optimal to yield significant results particularly 
since diet contributes only to a small extent to the 
vitamin D status compared to sun exposure in the 
studied area.29 In the area of the present study there 
is virtually no contribution of sun exposure during 
winter.
Table 3. Association between average daily intake of vitamin D3 through monthly supplemented cod liver oil in the 
winter during adolescence (ages 13–19) and MS risk for age at disease onset >19.
Cod liver 
oil
(ts/month)
Vitamin D3
(IU/day)
Cases n (%) Controls n (%) ORa 95% CI
Noneb – 525 (66.0) 784 (56.1) 1.00 –
1–15 ⩽ 200 79 (9.9) 160 (11.5) 0.74 0.55–0.99c
16–30 201–400 55 (6.9) 125 (9.0) 0.68 0.48–0.95c
31–45 401–600 14 (1.8) 38 (2.7) 0.58 0.31–1.08
46–60 601–800 32 (4.0) 104 (7.4) 0.46 0.31–0.70d
>60 >800 90 (11.3) 186 (13.3) 0.77 0.58–1.02
MS: multiple sclerosis; n: count; ts: teaspoons; IU: international units; OR: odds ratio; CI: confidence interval.
aAll estimates adjusted for age and sex; p-trend for association = 0.001, OR (95% CI) = 0.91 (0.87–0.96). Adjusting in addition for 
smoking before disease onset, history of infectious mononucleosis, sun exposure, body shape at age 15, education, and consumption 
of fatty fish: p trend = 0.025, OR (95% CI) = 0.94 (0.89–0.99). The effect estimate did not materially change when adjusting in addi-
tion for supplementation during adolescence in the summer.
bReference group consists of those who reported neither an intake of cod liver oil liquid nor capsules.
cP value < 0.05.
dP value < 0.0001.
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There are alternative explanations to our findings. 
Adolescence might be the most sensitive period in 
which vitamin D unfolds its observed immunomodu-
latory effects30 or is of importance in the terminal 
phase of brain development. Another explanation 
could be that vitamin D supplementation during dif-
ferent periods in life might not lead to comparable 
serum levels. No age-dependent difference was, how-
ever, experimentally found in how dietary vitamin 
amounts translate into serum levels.25
Our results might also be due to chance, but this is 
unlikely considering the strong association and con-
formity with previous findings. We adjusted the esti-
mates for other known environmental risk factors, 
but we cannot exclude the possibility of residual 
confounding.
Alternatively, the inverse association between cod 
liver oil use during adolescence and MS risk might be 
due to a longer period of exposure rather than the 
right timing. Adolescent cod liver oil users may be 
more likely to have additionally consumed the sup-
plement during the other periods resulting in a longer 
exposure. However, when analyzing continuous 
supplementation from birth over increasingly longer 
periods, the strength of association did not steadily 
increase. The longest supplementation period was 
less strongly associated with a reduced MS risk than 
the shorter ones.
Lastly, our findings might be due to the protective 
effect of other cod liver oil ingredients. Vitamin A and 
E as well as omega-3 fatty acids have become of 
interest as possible disease-modifying candidates of 
MS.31–33 Fewer studies focused on a risk-modulating 
potential and results are not consistent. A U-shaped 
pattern of association between serum vitamin A levels 
and MS risk was reported in a registry-based smaller 
cohort study.34 However, intake of carotenoids, vita-
min E and omega-3 fatty acids assessed by food fre-
quency questionnaires was unrelated to disease risk in 
two large cohorts of women.35,36 We cannot exclude 
the possibility that vitamin A in cod liver oil contrib-
uted to our findings. The dose-response relationship 
observed for use during adolescence might be attrib-
uted to a protective effect of vitamin A, which 
increases along with vitamin D in higher doses of cod 
liver oil. It is unknown whether this nutrient acts age-
dependently and could thus explain the findings on 
the timing of exposure to cod liver oil. Salzer and col-
leagues reported similar associations for younger par-
ticipants (16–26 years) as in the entire cohort.34 Even 
if age at exposure was not addressed in detail, this 
observation contradicts somewhat the presence of a 
strong age-dependent effect for vitamin A. Moreover, 
evidence for an age-varying action of vitamin D exists 
beyond studies focusing on dietary sources, and thus 
independent of vitamin A.4
The MS prevalence is lower in populations with con-
sumption of fish,37 and earlier studies suggested an 
inverse association between fish consumption and 
MS.4,38 Focusing on vitamin D-rich fatty fish, we 
found that consuming it during adolescence might be 
protective against the disease. The association was 
similar but no longer significant after adjusting for 
cod liver oil use. Our study might be underpowered to 
show subtle associations.
Previous studies investigating and comparing associ-
ations in different age periods in humans were smaller 
and could not account for all of the known risk factors 
of MS in the analyses.4,5 In this present large case-
control study we analyzed cod liver oil supplementa-
tion, widely used in the Norwegian population, as a 
dietary proxy for vitamin D intake and serum levels. 
Investigating and comparing various age periods we 
found evidence of clear age differences in how vita-
min D might affect MS risk even after adjusting for 
possible confounding.
Case-control studies, although efficient to conduct 
and suited to study past exposures in detail, are sub-
ject to methodological limitations. Despite the popu-
lation-based sampling of both cases and controls, 
selection bias could, for instance, be an issue consid-
ering the different response rates between both 
groups. Compared to those included in the study, indi-
viduals not responding could have a different distri-
bution of some of their main characteristics affecting 
the correlation between exposure and disease. We do 
not have any information on such a possible relation, 
but we found a higher proportion of controls with the 
highest level of education compared to the cases, indi-
cating a higher socioeconomic status in controls. We 
accounted for this by adjusting for confounding by 
education.
Recall bias is another potential threat to the validity of 
findings in case-control studies. Nevertheless, the 
overall proportion of participants reporting cod liver 
oil use did not differ among cases and controls, and it 
is unlikely that participants were biased in recalling 
the timing of this supplementation. Knowledge about 
the period in life most susceptible to MS risk modifi-
cation is not yet established.
In order to reduce the risk for misclassified responses, 
non-differential due to memory issues in general and 
 at Universitetsbiblioteket i Bergen on December 22, 2015msj.sagepub.comDownloaded from 
M Cortese, T Riise et al.
http://msj.sagepub.com 1863
differential due to deteriorating cognitive function in 
MS patients, only cases with a maximum disease 
duration of 10 years were eligible for the study. 
Furthermore, the age-period scale used to explore 
supplementation habits was adapted to the Norwegian 
school system to facilitate recall. In addition, partici-
pants were encouraged to ask their parents for help to 
correctly reconstruct past exposures if needed.
In conclusion, our findings suggest that adolescence 
might be an important postnatal age-period for an 
MS risk-reduction. Commonly used doses of vita-
min D contained in cod liver oil might contribute to 
modify MS risk when supplemented throughout 
adolescence. Further studies are needed to confirm 
our findings and to investigate whether higher doses 
might potentially be as protective during childhood 
or adulthood.
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